Drug companies should target drug plans, rather than physicians, consultant says

Silversides, Ann
January 2010
CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE21
Academic Journal
The article presents views of several experts regarding the focus of pharmaceutical companies. Paul Crotty, General Manager of IMS Health Canada Ltd. says that pharmaceutical companies should increase their focus on public and private drug plans rather than physicians. Bob Nakagawa, assistant deputy minister of pharmaceutical services for British Columbia feels that the current pharmaceutical purchasing system is inefficient and wasteful.


Related Articles

  • Pharma industry warned that huge profits in the face of the recession are no reason for complacency.  // CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE22 

    The article reports on the growth of the pharmaceutical sector in Canada during the global economic recession. Paul Crotty, General Manager of IMS Health Canada Ltd. says that the Canadian pharmaceutical market has redefined resilience by growing 7 percent during the economic recession. He...

  • Top-notch science op. Rollins, Gina // Modern Physician;Sep2002, Vol. 6 Issue 9, p22 

    Discusses the rewards and opportunities provided by the pharmaceutical industry to physician executives in the U.S. Main appeals of the industry to physicians; Perception on the industry; Qualities and skills that are important to physician executives in the pharmaceutical industry.

  • Meet the EAB. Booth, Shannon // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p40 

    No abstract available.

  • Dialysis: High Costs and Hidden Perils of a Treatment Guaranteed to All: Dialysis Data, Once Confidential, Shines Light on Clinic Disparities. Fields, Robin // Pro Publica;12/19/2010, p16 

    An introduction is presented which discusses several reports published within the journal on topics including steps taken by drug companies to retain control of physicians presentation, payments made to doctors and failure of Pentagon health plan in covering brain-damage therapy troops.

  • Drug Companies and Doctors: A Tight-Knit Community.  // People's Medical Society Newsletter;Jun2001, Vol. 20 Issue 3, p2 

    Deals with the influence that drug manufacturers have over the prescribing and professional behavior of physicians according to an article in the January 19, 2001 issue of the `Journal of the American Medical Association.'

  • Charging drug representatives for physician visits: Three leaders explain why and how.  // Formulary;Nov2002, Vol. 37 Issue 11, p594 

    Presents physicians' views about the charging of drug representatives for physician visits. Benefits to physicians of drug representative visits; Reasons for the implementation of fee-for-visit policy; Number of pharmaceutical firms that have agreed to the policy. INSETS: Facts at a glance:...

  • Physician Executives as Opinion Leaders in Biotechnology and Pharmaceuticals. Tan, Robert S. // Physician Executive;May/Jun2003, Vol. 29 Issue 3, p26 

    Discusses skills that a physician executive needs in order to become an advisor to biotechnology and pharmaceutical industries. Minimum benchmark of certification in clinical specialty; Advice customers about the product; Types of customers seeking opinions from physician executives.

  • Do Industry Ties Influence Patient Care Guidelines?  // Review of Optometry;3/15/2002, Vol. 139 Issue 3, p8 

    Investigates the relationships of physicians with pharmaceutical industry in relation to the writing of the patient care guidelines. Expansion of optometry practice; Influence of the relationship to the writing of the guidelines; Survey of the Journal of the American Medical Association...

  • A MARKETER'S CURE FOR ATTENTION DEFICIT DISORDER. Vanderveer, Richard B.; Pines, Noah M. // Medical Marketing & Media;May2003, Vol. 38 Issue 5, p64 

    Offers suggestions on how pharmaceutical firms can market their products to physicians. Psychology of persuasion; Message engineering; Expansion and diversification of the pharmaceutical industry's promotional voice.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics